Daraprim and Drug Pricing: The Impact of Shkreli's Advocacy on Healthcare Costs
Daraprim Price Increase Overview
In 2015, Martin Shkreli, then CEO of Turing Pharmaceuticals, raised the price of Daraprim, a life-saving anti-parasitic drug, from $13.50 to $750 per tablet. This 5,000% increase ignited a national outrage and sparked discussions on drug pricing.
Legal Implications and SCOTUS Decision
The recent denial by the Supreme Court to review Shkreli's case concludes a lengthy legal journey concerning drug pricing. The decision highlights the challenging landscape of healthcare regulation and the need for reforms in pharmaceutical pricing policies.
Impact on Drug Pricing Policies
This case not only symbolizes the controversies surrounding Martin Shkreli, but it also reflects broader issues in healthcare. Advocates argue that regulations must be established to prevent exorbitant pricing on life-saving medications.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.